High-Tech Blood Sugar Monitors May Help People With Type 1 Diabetes

Pair of studies found patients taking insulin injections had better levels with devices

Tuesday, January 24, 2017

TUESDAY, Jan. 24, 2017 (HealthDay News) -- A continuous glucose monitor helps people with type 1 diabetes who need insulin shots every day manage their blood sugar levels safely, two new studies suggest.

Also known as a CGM, the device constantly measures and reports a person's blood sugar levels. It does this via a thin wire sensor that's inserted underneath the skin, a transmitter worn on top of the skin, and a receiver (or smartphone) to gather the information.

"Few treatment options exist in the type 1 diabetes field. CGM is a treatment option that [people] should test if they have the option," said Dr. Marcus Lind, lead researcher on one of the studies. He's the chief physician of diabetology at Uddevalla Hospital in Sweden.

People with type 1 diabetes don't make enough insulin -- a hormone the body needs to use the carbohydrates in food for fuel. Because of this, people with type 1 rely on insulin injections or insulin delivered through a tiny catheter inserted under the skin and then attached to an insulin pump worn outside the body. People with type 1 diabetes using shots may need five or six insulin injections daily.

In people with type 2 diabetes, the body is no longer able to use insulin properly. Most (95 percent) of diabetes cases involve the type 2 form of the disease. Sometimes, people with type 2 diabetes also need to use insulin injections.

However, using insulin is a difficult balancing act -- too much or too little can cause problems, even life-threatening ones.

Aaron Kowalski is vice president of research for JDRF (formerly the Juvenile Diabetes Research Foundation). He noted, "Insulin is a dangerous but necessary drug for people with type 1 diabetes. These studies provide additional support for CGMs, which have been getting better and better. There's no doubt that someone on insulin will benefit from these devices."

When blood sugar levels go out of range -- either too high or too low -- a CGM's receiver sends an alarm, alerting the person with diabetes (or a parent for babies and children with diabetes) to the problem.

This is important because when blood sugar levels drop too low, people with diabetes can become disoriented, and if levels drop even further, they may pass out. Blood sugar levels that are too high and left untreated over time can cause complications such as kidney troubles, eye problems and heart disease.

Both studies used the Dexcom G4 CGM, and were funded by the manufacturer, Dexcom Inc. All participants used insulin shots to manage their type 1 diabetes.

The study led by Lind included 161 people with type 1 diabetes at 15 diabetes clinics in Sweden. Their average age was 44. The patients were randomly assigned to one of two groups.

The first group was given CGM for 26 weeks, and then conventional therapy for 26 weeks, with a period of no monitoring for 17 weeks in between. The other group did this in reverse and started with conventional therapy. Conventional therapy is self-monitoring of blood sugar levels.

The second study was led by Dr. Roy Beck, executive director of the Jaeb Center for Health Research in Tampa, Fla. This study included 158 patients. Their average age was 48. They were treated at 24 endocrinology practices across the country.

These volunteers were randomly given 24 weeks of CGM therapy or conventional therapy.

In both studies, blood sugar levels improved in both groups of patients. HbA1C levels dropped for those using CGMs. HbA1C is often called A1C for short. This test measures an average blood sugar level over the past two to three months. The results are expressed as a percentage. The American Diabetes Association goal for adults with diabetes is to get below 7 percent.

In Beck's study, there was a mean drop of 0.6 percent more in A1C for the CGM group versus the control group. In Lind's research, the decrease was about 0.4 percent more in those on CGMs than the control group. Both study authors said these drops were meaningful for patients.

Lind's group also saw a drop in severe low blood sugar (hypoglycemia) in people on a CGM.

"The satisfaction in our study was extremely high. CGMs have gotten smaller and more accurate. The benefits are greater and the hassles are less. It's worth it to carry around another device," Beck said.

The two studies were published Jan. 24 in Journal of the American Medical Association.

SOURCES: Marcus Lind, M.D., Ph.D., associate professor, diabetology, University of Gothenburg, and chief physician, diabetology, Uddevalla Hospital, Sweden; Roy Beck, M.D., Ph.D., executive director, Jaeb Center for Health Research, Tampa, Fla.; Aaron Kowalski, Ph.D., chief mission officer and vice president, research, JDRF; Jan. 24/31, 2017, Journal of the American Medical Association

HealthDay

News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services.